Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
Cash & Cash Equivalents
Takeda Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash & Cash Equivalents
¥494.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash & Cash Equivalents
¥682.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash & Cash Equivalents
¥426.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Cash & Cash Equivalents
¥305.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash & Cash Equivalents
¥393.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash & Cash Equivalents
¥179.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
Takeda Pharmaceutical Co Ltd
Glance View
In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.
See Also
What is Takeda Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
494.1B
JPY
Based on the financial report for Dec 31, 2024, Takeda Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 494.1B JPY.
What is Takeda Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-4%
Over the last year, the Cash & Cash Equivalents growth was 71%. The average annual Cash & Cash Equivalents growth rates for Takeda Pharmaceutical Co Ltd have been -12% over the past three years , -3% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet